HomeCompareGPHBF vs JNJ

GPHBF vs JNJ: Dividend Comparison 2026

GPHBF yields 1818181.82% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GPHBF wins by $1.881292041506834e+39M in total portfolio value
10 years
GPHBF
GPHBF
● Live price
1818181.82%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.881292041506834e+39M
Annual income
$1,881,088,520,285,862,000,000,000,000,000,000,000,000,000,000.00
Full GPHBF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — GPHBF vs JNJ

📍 GPHBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGPHBFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GPHBF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GPHBF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GPHBF
Annual income on $10K today (after 15% tax)
$154,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$1,598,925,242,242,982,800,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, GPHBF beats the other by $1,598,925,242,242,982,800,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GPHBF + JNJ for your $10,000?

GPHBF: 50%JNJ: 50%
100% JNJ50/50100% GPHBF
Portfolio after 10yr
$9.40646020753417e+38M
Annual income
$940,544,260,142,931,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GPHBF
No analyst data
Altman Z
-33.9
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GPHBF buys
0
JNJ buys
0
No recent congressional trades found for GPHBF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGPHBFJNJ
Forward yield1818181.82%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1.881292041506834e+39M$30.5K
Annual income after 10y$1,881,088,520,285,862,000,000,000,000,000,000,000,000,000,000.00$4,749.88
Total dividends collected$1.8812787257762296e+39M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GPHBF vs JNJ ($10,000, DRIP)

YearGPHBF PortfolioGPHBF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$181,828,882$181,818,181.82$10,594$274.49+$181.82MGPHBF
2$3,089,895,182,531$3,089,700,625,627.56$11,294$360.69+$3089895.17MGPHBF
3$49,073,017,437,436,030$49,069,711,249,590,720.00$12,133$476.91+$49073017437.42MGPHBF
4$728,383,416,252,417,800,000$728,330,908,123,759,800,000.00$13,156$635.42+$728383416252417.88MGPHBF
5$10,104,056,111,960,643,000,000,000$10,103,276,741,705,254,000,000,000.00$14,432$854.61+$10104056111960643584.00MGPHBF
6$130,993,581,604,683,890,000,000,000,000$130,982,770,264,644,100,000,000,000,000.00$16,056$1,162.76+$1.3099358160468389e+23MGPHBF
7$1,587,168,426,262,404,800,000,000,000,000,000$1,587,028,263,130,088,000,000,000,000,000,000.00$18,175$1,604.53+$1.5871684262624049e+27MGPHBF
8$17,972,766,048,075,827,000,000,000,000,000,000,000$17,971,067,777,859,724,000,000,000,000,000,000,000.00$21,009$2,252.68+$1.7972766048075828e+31MGPHBF
9$190,206,748,572,353,800,000,000,000,000,000,000,000,000$190,187,517,712,682,400,000,000,000,000,000,000,000,000.00$24,911$3,229.73+$1.9020674857235377e+35MGPHBF
10$1,881,292,041,506,834,000,000,000,000,000,000,000,000,000,000$1,881,088,520,285,862,000,000,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$1.881292041506834e+39MGPHBF

GPHBF vs JNJ: Complete Analysis 2026

GPHBFStock

G6 Materials Corp., through its subsidiaries, develops, manufactures, and sells proprietary products based on graphene and other materials. It offers air purification materials; general purpose, flexible, high-temperature, and room temperature adhesives; advanced materials and composite formulations for businesses and daily life industries, as well as air, sea, and land applications. The company also provides a suite of graphene products through its e-commerce platform. It serves various industries, including aerospace, automotive, healthcare, marine, medical prosthetics, and various branches of the military. The company was formerly known as Graphene 3D Lab Inc. and changed its name to G6 Materials Corp. in January 2020. G6 Materials Corp. was incorporated in 2011 and is headquartered in Ronkonkoma, New York.

Full GPHBF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GPHBF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GPHBF vs SCHDGPHBF vs JEPIGPHBF vs OGPHBF vs KOGPHBF vs MAINGPHBF vs ABBVGPHBF vs MRKGPHBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.